What question did this study set out to answer?

To determine the survival outcomes of patients with HER2-positive breast cancer who achieved pCR treated with adjuvant trastuzumab alone versus trastuzumab plus pertuzumab.

May 29, 2026Journal of Clinical Oncology

Adjuvant trastuzumab with or without pertuzumab after pathologic complete response to neoadjuvant HER2-targeted therapy and chemotherapy in HER2-positive breast cancer: A retrospective cohort study.

View Full Paper

Ask AI

Bookmark

Authors

JFJames FradinMedical College of Wisconsin AHAmber HaugenMedical College of Wisconsin YYYushan YangFroedtert Hospital

Discussion

Member takes

Implication

Retrospective cohort study compares adjuvant trastuzumab with or without pertuzumab after pCR in HER2-positive breast cancer, suggesting limited benefit of dual blockade.

Key Points

To determine the survival outcomes of patients with HER2-positive breast cancer who achieved pCR treated with adjuvant trastuzumab alone versus trastuzumab plus pertuzumab.
Conducted a single-center retrospective cohort study of 128 patients with HER2-positive invasive breast cancer achieving pCR after neoadjuvant treatment.
Compared 109 patients receiving adjuvant trastuzumab alone with 19 patients receiving trastuzumab plus pertuzumab over a median follow-up of 9.28 years.
Evaluated associations with comorbidity using the Charlson comorbidity index and ECOG performance status.
Five-year recurrence-free survival was 94% with trastuzumab and 95% with trastuzumab plus pertuzumab (95% CI for both).
No significant difference in overall survival (96% vs 100%) between the two groups after 5 years.
Additional estimated cost for pertuzumab treatment was approximately $590 per cycle compared to trastuzumab alone.

Cite This Study

Fradin et al. (2026) studied this question.

synapsesocial.com/papers/6a192d2dfab5b468c4415fbb https://doi.org/10.1200/jco.2026.44.16_suppl.e12503

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study compares adjuvant trastuzumab with or without pertuzumab after pCR in HER2-positive breast cancer, suggesting limited benefit of dual blockade.

Adjuvant trastuzumab with or without pertuzumab after pathologic complete response to neoadjuvant HER2-targeted therapy and chemotherapy in HER2-positive breast cancer: A retrospective cohort study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Adjuvant trastuzumab with or without pertuzumab after pathologic complete response to neoadjuvant HER2-targeted therapy and chemotherapy in HER2-positive breast cancer: A retrospective cohort study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider